Anti-human follicle-stimulating hormone rabbit monoclonal antibody and application thereof
By developing anti-human follicle stimulating hormone rabbit monoclonal antibody with high specificity and affinity, the problem of poor anti-human FSH protein antibody specificity and anti-interference ability in the prior art is solved, and FSH on cell/tissue surface is achieved High accuracy and sensitivity detection, suitable for immunohistochemistry and immunofluorescence analysis.
Patent Information
- Application Number
- CN202411146806.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-21
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2044-08-21
AI Technical Summary
In the prior art, the specificity and anti-interference ability of anti-human FSH protein antibodies are poor, making it difficult to directly use in immunologic detection of cells/tissues, especially when the target antigen FSH content is low and the cell component disturbs factors are interfering with the cell component. Many, resulting in nonspecific binding.
A rabbit monoclonal antibody against human follicle stimulating hormone has been developed, which has good specificity, high affinity and excellent anti-interference ability, and can specifically recognize and bind FSH on the surface of human cells/tissue, which is suitable for High specificity, high accuracy and high sensitivity detection, suitable for immunohistochemistry and immunofluorescence analysis.
It improves the sensitivity, accuracy and reliability of cell/tissue surface FSH detection, and is particularly suitable for immunohistochemistry and immunofluorescence analysis, and is cross-reactive to human and murine homologous FSH proteins, and has wide applicability.
Smart Images

Figure CN119039437A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of antibody preparation, in particular to rabbit monoclonal antibodies against human follicle stimulating hormone and applications thereof. Background Art
[0002] Follicle-stimulating hormone (FSH), also known as follicle-stimulating hormone or follicle-stimulating hormone, is a glycoprotein hormone synthesized and secreted by the anterior pituitary basophils of animals. Its main function is to promote and maintain normal gonadal development and reproductive function. The FSH molecule is a heterodimer composed of two subunits, the α subunit and the β subunit, which are non-covalently bound. The α subunit of human FSH (UniProt number: P01215) consists of 92 amino acids and has a theoretical molecular weight of about 12KDa. The β subunit of human FSH (UniProt number: P01225) consists of 111 amino acid residues and has a molecular weight of about 12.5kDa. There are N-glycosylation sites at the 7th and 24th asparagine residues. Neither the α nor the β subunit alone has biological activity, and can only play a biological role when the two are combined.
[0003] FSH is a gonadotropin. After being secreted into the blood, it will specifically act on the lower endocrine target glands (ovaries or testicles), and then regulate the activity of tissue cells throughout the body through the target gland hormones. It plays a key role in the secretion and regulation of hormones in the hypothalamus-pituitary-gonad reproductive axis. The production of FSH is controlled by the hypothalamic gonadotropin-releasing hormone and is also regulated by the feedback of ovarian estrogen (E2). In men, its function is to promote the maturation of testicular seminiferous tubules and sperm production; in women, its function is to promote the development and maturation of follicles, and to cooperate with luteinizing hormone (LH) to promote the secretion of estrogen and ovulation of mature follicles, and participate in the formation of normal menstruation. FSH plays an important role in maintaining reproductive health and regulating fertility. By measuring the FSH content, we can understand the endocrine function of the pituitary, and indirectly understand the functional status of the hypothalamus and ovaries, which is very helpful for the differential diagnosis of pituitary or hypothalamic amenorrhea. Elevated FSH can be seen in diseases such as primary ovarian dysfunction, ovarian ovulation disorder, primary or secondary amenorrhea, galactorrhea, male infertility, testicular spermatogonial carcinoma, primary hypogonadism, early anterior pituitary function, and giant cell degenerative lung cancer; decreased FSH can be seen in diseases such as pituitary or hypothalamic hypogonadism, adenohypophysis, Sheehan syndrome, menstrual disorders, polycystic ovary syndrome, etc.
[0004] At present, FSH detection generally adopts chemiluminescent immunoassay and electrochemiluminescent immunoassay, but the aforementioned methods cannot be quickly qualitatively detected by direct detection of tissues or cells at the lesion site. The reason is that during cell or tissue biopsy, the content of target antigen FSH is usually low and there are many interfering factors of cell components. The low specificity and / or affinity of antibodies can easily lead to non-specific binding. Therefore, there are few antibodies on the market that can be used for cell and / or tissue immunoassay applications such as immunohistochemistry and immunofluorescence analysis. Therefore, it is urgent to develop a high-specificity FSH antibody suitable for cell / tissue detection. Summary of the invention
[0005] In view of the problems that the anti-human FSH protein antibodies in the prior art have poor specificity and anti-interference ability and are difficult to be directly used in immunological detection of cell / tissue detection, the present invention provides a rabbit monoclonal antibody against human follicle stimulating hormone, which can specifically recognize and bind to FSH on the surface of human cells / tissues, has good specificity, high affinity and excellent anti-interference ability, and is suitable for high-specificity, high-accuracy and high-sensitivity detection of FSH on the surface of cells / tissues. The present invention further provides the use of the antibody in the preparation of immunological detection reagents and / or kits for human follicle stimulating hormone and related immunological detection kits. To achieve the aforementioned purpose, the present invention is specifically implemented through the following technical solutions:
[0006] The first aspect of the present invention provides a rabbit monoclonal antibody against human follicle stimulating hormone, comprising a light chain variable region and a heavy chain variable region, wherein the amino acid sequences of the complementary determining regions CDR1, CDR2 and CDR3 on the light chain variable region are respectively shown as SEQ ID NO.3-5; the amino acid sequences of the complementary determining regions CDR1, CDR2 and CDR3 on the heavy chain variable region are respectively shown as SEQ ID NO.8-10.
[0007] Furthermore, the amino acid sequence of the light chain variable region is shown in SEQ ID NO.2, and the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO.7.
[0008] Furthermore, the rabbit monoclonal antibody also includes a light chain constant region and a heavy chain constant region, the light chain constant region and the light chain variable region constitute a light chain, the heavy chain constant region and the heavy chain variable region constitute a heavy chain, wherein the light chain constant region is a κ chain, and the heavy chain is of IgG type.
[0009] Furthermore, the amino acid sequence of the light chain is shown in SEQ ID NO.1, and the amino acid sequence of the heavy chain is shown in SEQ ID NO.6.
[0010] Furthermore, the rabbit monoclonal antibody is a full-length antibody or its antigen-binding region; the antigen-binding region is selected from the group consisting of Fab fragment, F(ab)2 Fragment, Fv fragment, (Fv) 2 Fragments, scFv fragments and sc(Fv) 2 At least one of the fragments.
[0011] The second aspect of the present invention provides a nucleic acid molecule, a recombinant vector comprising the nucleic acid molecule or a host cell comprising the nucleic acid molecule, wherein the nucleic acid molecule encodes the rabbit monoclonal antibody against human follicle stimulating hormone as described above.
[0012] Furthermore, the recombinant vector is an expression vector pBR322, and the host cell is a human kidney epithelial cell.
[0013] The third aspect of the present invention provides the use of the above-mentioned rabbit monoclonal antibody against human follicle stimulating hormone in the preparation of a reagent and / or a kit for immunoassay of human follicle stimulating hormone.
[0014] The fourth aspect of the present invention provides a human follicle stimulating hormone immunoassay kit, the kit comprising the above-mentioned anti-human follicle stimulating hormone rabbit monoclonal antibody or its antibody conjugate, the antibody conjugate is formed by connecting the rabbit monoclonal antibody to a detection marker.
[0015] Furthermore, the kit is an immunohistochemistry kit or an immunofluorescence kit.
[0016] The advantages and positive effects of the present invention are:
[0017] The antibody provided by the present invention can specifically recognize and bind to follicle stimulating hormone (FSH) on the surface of human cells / tissues, has good specificity, high affinity and excellent anti-interference ability, and is useful for improving sensitivity, accuracy and reliability when used for immunoassay to directly detect and determine whether tissues / cells express FSH, and is particularly suitable for immunohistochemical analysis and immunofluorescence analysis. In addition, the antibody of the present invention has cross-reactivity to human and mouse homologous FSH proteins and has wide applicability. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the following briefly introduces the drawings required for use in the description of the embodiments. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative work.
[0019] Figure 1 This is the SDS-PAGE gel image of the recombinant human FSH protein of Example 1 of the present invention;
[0020] Figure 2This is a diagram showing the serum titer test results of rabbits immunized with the recombinant human FSH protein according to Example 2 of the present invention;
[0021] Figure 3 A map of the mammalian expression vector pRB322 used to construct an anti-human FSH protein rabbit monoclonal antibody expression vector in Example 2 of the present invention, from left to right, respectively, the vectors carrying the antibody light chain constant region and heavy chain constant region in advance;
[0022] Figure 4 This is a staining diagram of Example 3 of the present invention using anti-human FSH protein antibodies to detect FSH expression in different tissue section samples by immunohistochemistry, from left to right, human pituitary tissue, human liver tissue and mouse pituitary tissue;
[0023] Figure 5 This is a fluorescence staining diagram of the FSH expression in human pituitary tissue slice samples detected by immunofluorescence method using anti-human FSH protein antibody in Example 3 of the present invention. DETAILED DESCRIPTION
[0024] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with embodiments. The embodiments described herein are only used to explain the present invention and are not used to limit the present invention.
[0025] Based on the information contained in the present invention, it is easy for those skilled in the art to make various changes to the precise description of the present invention without departing from the spirit and scope of the appended claims. It should be understood that the scope of the present invention is not limited to the defined processes, properties or components, because these embodiments and other descriptions are only for the purpose of illustrating specific aspects of the present invention. In fact, various changes that a person skilled in the art or related fields can obviously make to the embodiments of the present invention are covered within the scope of the appended claims.
[0026] In order to better understand the present invention but not to limit the scope of the present invention, all the numbers and other numerical values used in the present invention to express the amount, percentage, etc. should be understood as modified by the word "about" in all cases. Therefore, unless otherwise specified, the numerical parameters listed in the specification and the appended claims are approximate values, which may be changed according to the different ideal properties to be obtained. Each numerical parameter should at least be regarded as obtained according to the reported significant figures and by conventional rounding methods.
[0027] In addition, it should be noted that, unless otherwise defined, in the context of the present invention, the scientific and technical terms used should have the meanings commonly understood by those of ordinary skill in the art.
[0028] The meaning of the terms "include", "comprising", "containing", "having" and the like is non-restrictive, that is, other steps and other ingredients that do not affect the result may be added. The term "and / or" should be regarded as a specific disclosure of each of the two specified features or components with or without the other. For example, "A and / or B" is regarded as including the following situations: (i) A, (ii) B and (iii) A and B.
[0029] The terms "rabbit monoclonal antibody", "monoclonal antibody", "rabbit antibody" and "rabbit monoclonal antibody" and other similar terms have the same meaning and, unless otherwise specified, refer to antibodies that specifically bind to human follicle stimulating hormone (FSH). The modifier "rabbit" indicates that the complementarity determining region (CDR) of the antibody is derived from a rabbit immunoglobulin sequence.
[0030] An antibody is an immunoglobulin molecule that can specifically bind to a target antigen or epitope through at least one antigen recognition site located in the variable region of the immunoglobulin molecule. In the present invention, the term "antibody" should be interpreted in the broadest sense and includes different antibody structures, including but not limited to so-called full-length antibodies, antibody fragments, and their genetic or chemical modifications, as long as they exhibit the desired antigen-binding activity.
[0031] A typical antibody molecule (full-length antibody) consists of two identical light chains (L) and two identical heavy chains (H). Light chains can be divided into two types, namely κ chain and λ chain; heavy chains can be classified into five types, namely μ, δ, γ, α and ε chains, and antibodies are defined as IgM, IgD, IgG, IgA and IgE, respectively. The amino acid sequences near the N-terminus of the heavy and light chains vary greatly, while the amino acid sequences of other parts are relatively constant. The regions near the N-terminus of the light and heavy chains where the amino acid sequences vary greatly are called variable regions (V), and the regions near the C-terminus where the amino acid sequences are relatively stable are called constant regions (C). The heavy chain variable region (VH) and the light chain variable region (VL) are usually the most variable parts of the antibody and contain antigen recognition sites. The VH and VL regions can be further subdivided into hypervariable regions (HVR) and framework regions (FR). The hypervariable regions are also called complementarity determining regions (CDRs), which are ring-shaped structures. The heavy chain CDR and the light chain CDR are closely together and cooperate with each other through the FR region, forming a surface that can complement the three-dimensional structure of the target antigen or epitope, which determines the specificity of the antibody and is the site where the antibody recognizes and binds to the antigen. The FR region is the more conservative part of VH and VL. They are generally in a β-folded configuration and are connected by three CDRs that form a connecting loop. Each VH and VL is usually composed of three CDRs and four FRs, arranged from the amino terminus to the carboxyl terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.
[0032] CDRs and FRs can be identified according to the Kabat definition, the Chothia definition, the accumulation of both the Kabat definition and the Chothia definition, the AbM definition, the contact definition, the IMGT unique numbering definition and / or the conformational definition, or any CDR determination method known in the art. As used herein, the Kabat numbering system is used to define.
[0033] The light chain constant region (CL) and the heavy chain constant region (CH) are not directly involved in the binding of antibodies to antigens, but they exhibit different effector functions, such as participating in antibody-dependent cytotoxicity of antibodies. The length of CL of different types of Ig (κ or λ) is basically the same, but the length of CH of different classes of Ig is different, such as IgG, IgA and IgD include CH1, CH2 and CH3, while IgM and IgE include CH1, CH2, CH3 and CH4. The amino acid sequences of the heavy chain and light chain constant regions of antibodies are well known in the art.
[0034] A full-length antibody is the most complete antibody molecular structure and has a typical Y-shaped molecular structure. Therefore, in the context of the present invention, "full-length antibody", "complete antibody" and "Y-shaped antibody" have the same meaning and can be used interchangeably.
[0035] Antibody fragments are one or more parts or fragments of a full-length antibody, which essentially retain the same biological function or activity as the full-length form. Specifically, antibody fragments at least include the same CDR region as the full-length antibody, and more preferably have the same variable region, thereby retaining complete antigen recognition and binding sites, and can bind to the same antigen as the full-length antibody, especially to the same epitope. In typical examples, antibody fragments include: Fab, F(ab) 2 , Fab', F(ab') 2 、Fv、(Fv) 2 , scFv, sc(Fv) 2 These antibody fragments can be obtained by conventional techniques in the art.
[0036] (i) Fab: Antigen-binding fragment (Fab) is a monovalent fragment consisting of a complete light chain (variable region and constant region) and a portion of the heavy chain (variable region and first constant region). Fab and F(ab') can be obtained by proteolytic cleavage of the full-length antibody. 2 , Fab' and other fragments. For example, under the action of papain, IgG can be degraded into two Fab fragments and one Fc fragment; under the action of pepsin, IgG can be degraded into one F(ab') 2 fragment and a pFc' fragment. F(ab') 2 The fragment is further reduced to form two Fab' fragments. Since Fab has an antigen binding region and a partial constant region, it not only has the same antibody-antigen affinity and excellent tissue penetration as scFv, but also has a more stable structure.
[0037] (ii) F(ab) 2 : A bivalent fragment consisting of two Fabs connected by a disulfide bridge in the hinge region.
[0038] (iii) Fv: The variable fragment (Fv) is located at the N-terminus of the antibody Fab fragment, contains only the variable region, and is composed of the variable regions of a light chain and a heavy chain. It is a dimer of VH and VL non-covalently bound (VH-VL dimer). The three CDRs of each variable region interact with each other to form an antigen binding site on the surface of the VH-VL dimer, which has the ability to recognize and bind to antigens, although the affinity is lower than that of the intact antibody.
[0039] (iv)(Fv) 2: Consists of two Fv fragments covalently linked together.
[0040] (v) scFv: Single-chain variable fragment (scFv) is an Fv fragment composed of a single polypeptide chain, which is composed of a heavy chain variable region (VH) and a light chain variable region (VL) connected by a flexible linker (generally composed of 10-25 amino acids), which retains the binding specificity of the original antibody to the antigen. The linker in the present invention is not particularly limited as long as it does not hinder the expression of the antibody variable regions connected to its two ends. Compared with full-length antibodies, scFv has the characteristics of small molecular weight, so it has higher penetration and lower immune side effects.
[0041] (vi)sc(Fv) 2 The fragment is composed of two heavy chain variable regions and two light chain variable regions connected by a linker or the like.
[0042] In some embodiments, the full-length sequence of the antibody or antibody fragment of the present invention may include a complementary determining region (CDR) and a framework region (FR) from a rabbit immunoglobulin sequence. In other embodiments, the antibody may include amino acid residues encoded by non-rabbit immunoglobulin sequences, for example, humanized antibodies, chimeric antibodies, etc., to reduce the body's rejection reaction while maintaining the required specificity and affinity. The term "chimeric antibody" refers to a portion of an antibody derived from a specific source or species, while the rest is derived from a different source or species. The term "humanized antibody" is a chimeric antibody of a non-human antibody such as a rabbit antibody's CDR region and a mouse FR region. In some cases, the variable region of a non-human antibody is combined with a constant region of a human antibody, such as a mouse-rabbit chimeric antibody; in other cases, the CDR region of a non-human antibody is combined with a FR region and a constant region derived from a human antibody sequence, that is, the CDR region of a non-human antibody is grafted onto a mouse antibody framework (FR) sequence, and this framework sequence is derived from a single or multiple other mouse antibody variable region framework sequences. In the present invention, the CDR region in the chimeric antibody or humanized antibody is derived from a rabbit-derived CDR region.
[0043] The terms "monoclonal antibody" or "single antibody" and the like are used interchangeably and refer to a homogeneous antibody population, i.e., the individual antibodies constituting the population are identical except for a small amount of mutations and / or post-translational modifications (e.g., isomerization, amidation) that may occur naturally. "Monoclonal antibodies" are highly specific and exhibit a single binding specificity and affinity for the same or substantially identical epitopes on an antigen. The modifier "monoclonal" indicates that the antibody is obtained from a substantially homogeneous antibody population and should not be construed as limiting the source or preparation method of the antibody. The antibody can be prepared by a variety of methods, including but not limited to hybridoma methods, phage display methods, yeast display methods, recombinant DNA methods, single cell screening, or single cell sequencing methods.
[0044] The term "specific binding" is a well-known term in the art, and a molecule exhibits "specific binding" if it reacts with a specific target antigen or epitope more frequently, more rapidly, longer lastingly, and / or with greater affinity than with other target antigens or epitopes. "Specific binding" or "preferential binding" does not necessarily require (although it can include) exclusive binding.
[0045] In order to make the above-mentioned objects, features and advantages of the present invention more obvious and easy to understand, specific embodiments of the present invention are described in detail below with reference to the accompanying drawings.
[0046] An embodiment of the present invention provides a rabbit monoclonal antibody against human follicle stimulating hormone (FSH), comprising a light chain variable region and a heavy chain variable region, wherein the light chain variable region and the heavy chain variable region both include three complementary determining regions (CDRs), which are named CDR1, CDR2 and CDR3, respectively, wherein the amino acid sequences of CDR1, CDR2 and CDR3 on the light chain variable region are shown in SEQ ID NO.3, SEQ ID NO.4 and SEQ ID NO.5, respectively; the amino acid sequences of CDR1, CDR2 and CDR3 on the heavy chain variable region are shown in SEQ ID NO.8, SEQ ID NO.9 and SEQ ID NO.10, respectively.
[0047] The present invention uses human recombinant FSH heterodimer protein as antigen to immunize rabbits, and then based on the monoclonal antibody development technology of single B lymphocyte screening and cultivation, obtains rabbit-derived monoclonal antibodies for identifying and binding human follicle stimulating hormone (FSH). The specificity of antibody recognition antigen is detected by immunofluorescence method and immunohistochemistry method, showing that the antibody of the present invention can accurately distinguish positive and negative tissue samples, has specific coloring in positive tissue samples expressing FSH protein, and the antibody binds to FSH antigen and is accurately positioned, which is consistent with theoretical expectation, and the positive staining is clear and bright, the background is clean, and there is no non-specific coloring in negative tissue samples that do not express FSH protein. It can be seen that the antibody of the present invention can specifically identify the FSH protein on the surface of cells / tissues, has good specificity, higher affinity and excellent anti-interference ability, and is used for immunoassay direct detection to determine whether tissues / cells express FSH, which is conducive to improving detection sensitivity, accuracy and reliability, and is particularly suitable for immunohistochemical analysis and immunofluorescence analysis. In addition, the antibody of the present invention has cross-reactivity to human and mouse homologous FSH proteins, and has wide applicability.
[0048] Optionally, the light chain variable region and the heavy chain variable region each include four framework regions (FRs), and the four FRs and three CDRs are arranged alternately in sequence to form a variable region. The amino acid sequence of the light chain variable region (VL) of the antibody of the present invention is shown in SEQ ID NO.2, and the amino acid sequence of the heavy chain variable region (VH) is shown in SEQ ID NO.7.
[0049] Optionally, the antibody of the present invention further comprises a light chain constant region and a heavy chain constant region, CL and VL constitute a complete light chain (FL), and CH and VH constitute a complete heavy chain (FH). The constant region of an antibody can usually be obtained by public query, such as: searching for rabbit IgG gamma C reign to obtain CH through the IMGT online database (www.imgt.org), and searching for rabbit IgG Kappa C reign to obtain CL. Specifically, the amino acid sequence of the antibody light chain is shown in SEQ ID NO.1, the light chain constant region is a κ chain, the amino acid sequence of the heavy chain is shown in SEQ ID NO.6, and the heavy chain is of IgG type.
[0050] It should be noted that the antibody of the present invention can be a full-length antibody (having a typical Y-shaped molecular structure) or an antigen binding region of the full-length antibody; the antigen binding region refers to a polypeptide that substantially maintains the same biological function or activity as the full-length antibody. Specifically, the antigen binding region includes the CDR region as described above, and more preferably has the variable region as described above, thereby retaining a complete antigen recognition and binding site, and being able to bind to the same antigen as the full-length antibody, especially to the same epitope. Optionally, the antigen binding region is selected from Fab, F(ab) 2, Fab', F(ab') 2 、Fv、(Fv) 2 , scFv and sc(Fv) 2 These antigen-binding regions can be obtained by conventional techniques in the art.
[0051] Yet another embodiment of the present invention provides a nucleic acid molecule, a recombinant vector comprising the nucleic acid molecule, or a host cell comprising the nucleic acid molecule, wherein the nucleic acid molecule encodes the rabbit monoclonal antibody against human follicle stimulating hormone as described above.
[0052] Nucleic acid molecules can be in the form of DNA (such as cDNA or genomic DNA or synthetic DNA) or RNA (such as mRNA or synthetic RNA). DNA can be single-stranded or double-stranded, and can also be a coding strand or a non-coding strand.
[0053] The sequence of the nucleic acid molecule can be derived from the antibody amino acid sequence by conventional means such as codon coding rules. The full-length sequence of the nucleic acid molecule or its fragment can usually be obtained by PCR amplification, recombination or artificial synthesis. The obtained nucleic acid molecule is inserted into an expression vector, then introduced into a host cell, and cultured under specific conditions to express the antibody.
[0054] The original vector for constructing the recombinant vector is any conventional vector in the art, as long as it can carry the nucleic acid molecule. Typical vectors include plasmids (such as pBR322, pUC series, pET series, pGEX series), viral vectors, bacteriophages (such as λgt4λB, λ-Charon, λΔz1 and M13), cosmids and mini-chromosomes. The vector can be a cloning vector (i.e., used to transfer nucleic acid molecules to a host and multiply in a host cell) or an expression vector (i.e., containing the necessary genetic elements to allow the nucleic acid molecules inserted into the vector to be expressed in the host cell). The nucleic acid molecules of the present invention can be inserted into a suitable vector to form a cloning vector or an expression vector carrying the nucleic acid molecule. This is a well-known technique in the art and will not be described in detail herein.
[0055] The nucleic acid molecules encoding the antibodies FL and FH of the present invention can be inserted into two vectors, respectively, which can be introduced into the same or different host cells. When the heavy chain and the light chain are expressed in different host cells, each chain can be separated from the host cell expressing it, and the separated heavy chain and light chain are mixed and incubated under suitable conditions to form antibodies. In other embodiments, the nucleic acid molecules of antibodies FL and FH can also be cloned into a vector, and each nucleic acid sequence is connected to a suitable promoter downstream; for example, each nucleic acid sequence encoding the heavy chain and the light chain can be operably connected to different promoters, or the nucleic acid sequence encoding the heavy chain and the light chain can be operably connected to a single promoter, so that both the heavy chain and the light chain can be expressed by the same promoter. The choice of expression vector / promoter depends on the type of host cell used to produce the antibody.
[0056] The recombinant vector is transfected or transformed into the host cell using conventional techniques. When the host is a prokaryotic organism such as Escherichia coli, competent cells that can absorb DNA are harvested after the exponential growth phase and treated with CaCl 2 MgCl 2 treatment; it can also be carried out by microinjection, electroporation or liposome packaging, etc. When the host is a eukaryotic organism, the following DNA transfection methods can be used: calcium phosphate coprecipitation, microinjection, electroporation, liposome packaging or particle bombardment to achieve gene introduction.
[0057] The host cell can be a prokaryotic or eukaryotic cell. Examples of prokaryotic host cells that can be used in the present invention include, but are not limited to, Escherichia coli (e.g., DH5α, JM109, BL21, W3110), Bacillus (e.g., Bacillus subtilis, Bacillus thuringiensis), and Enterobacteriaceae strains (e.g., Salmonella typhimurium, Serratia marcescens), and Pseudomonas. Examples of eukaryotic host cells that can be used for transformation include, but are not limited to, yeast, insect cells, and animal cells, such as Drosophila S2 or Sf9 cells, mammalian CHO, CHO DG44, CHO-S, COS-7, 293 series cells, HepG2, Huh7, 3T3, RIN, MDCK, and HEK293 cell lines. After obtaining a host cell transfected or transformed with a recombinant vector as described above, the antibody can be expressed by culturing under suitable conditions, and then separated to obtain a purified antibody.
[0058] In a preferred embodiment, the recombinant vector is the expression vector pBR322, and the host cell is a human kidney epithelial cell (293F cell).
[0059] Still another embodiment of the present invention provides the use of the above-mentioned rabbit monoclonal antibody against human follicle stimulating hormone in the preparation of a reagent and / or a kit for immunoassay of human follicle stimulating hormone.
[0060] The advantages of using the rabbit monoclonal antibody against human follicle stimulating hormone (FSH) in preparing immunoassay human FSH detection reagents and / or kits are the same as the advantages of the rabbit monoclonal antibody against human FSH over the prior art as described above, and will not be repeated here.
[0061] Based on the same inventive concept, an embodiment of the present invention further provides a human follicle stimulating hormone immunoassay kit, which includes the rabbit monoclonal antibody or antibody conjugate against human follicle stimulating hormone as described above, wherein the antibody conjugate is formed by connecting the rabbit monoclonal antibody to a detection marker.
[0062] The advantages of the human follicle stimulating hormone immunoassay kit over the prior art are the same as the advantages of the rabbit monoclonal antibody against human FSH over the prior art as described above, and will not be repeated here.
[0063] It should be noted that the antibody of the present invention can be used alone or combined or coupled with a detection marker to form an antibody conjugate. In some embodiments, the antibody of the present invention is used as an antigen-binding antibody, which specifically recognizes and binds to FSH in the sample to be tested, and then the qualitative or quantitative detection of FSH is achieved by analyzing the detection marker signal connected thereto; in other embodiments, the anti-human FSH antibody (as a primary antibody or capture antibody) is not labeled, and the detection marker is coupled to a secondary antibody (as a detection antibody) or other molecules that can bind to the primary antibody. For example, if the anti-human FSH antibody is a rabbit IgG antibody, then the secondary antibody can be an anti-rabbit IgG antibody, thereby analyzing the changes in the detection marker signal generated after the secondary antibody specifically binds to the antibody of the present invention, and achieving qualitative or quantitative detection of FSH.
[0064] The detection label is used to generate a recognizable signal change to identify the sample to be tested according to the signal change. The detection label includes, but is not limited to: biotin, fluorescent dyes (such as umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride), fluorescent proteins (such as allophycocyanin, phycoerythrin, PerCP and phycocyanin), enzymes (such as alkaline phosphatase, acid phosphatase, β-galactosidase, glucose oxidase, horseradish peroxidase, acetylcholinesterase, avidin), colloidal gold, colored magnetic beads, latex particles, radionuclides, detection antibodies or combinations thereof.
[0065] Immunoassay methods include, but are not limited to, ELISA (Enzyme linked immunosorbentassay), ELISPOT (Enzyme-linked Immunospot), IHC (Immunohistochemistry), IF (Immunofluorescence), WB (Western blot), IP (Immunoprecipitation) and FC (Flow Cytometry). Therefore, the kit can be an ELISA kit, an ELISPOT kit, an immunohistochemistry kit, an immunofluorescence kit, an immunoblotting kit or a flow cytometry kit.
[0066] In a preferred embodiment, the kit is an immunohistochemistry kit or an immunofluorescence kit.
[0067] The present invention is further described below in conjunction with specific examples. The experimental methods in the following examples where specific conditions are not specified are usually performed under conventional conditions, such as the conditions described in the Molecular Cloning Laboratory Guide (Fourth Edition) published by Cold Spring Harbor Laboratory, or usually under the conditions recommended by the manufacturer.
[0068] Example 1 Preparation of human follicle stimulating hormone (FSH) antigen
[0069] The amino acid fragments of the 25th (inclusive) to 116th (inclusive) amino acids of the human follicle stimulating hormone (FSH) α subunit (NCBI gene accession number NM_000735.4, protein accession number: NP_000726.1) and the amino acid fragments of the 21st (inclusive) to 129th (inclusive) amino acids of the human FSH β subunit (NCBI gene accession number NM_000510.4, protein accession number NP_000501.1) were connected with a 3×G4S connecting peptide (underlined) as antigens. The recombinant genes corresponding to the antigens were synthesized by Jiangsu Saisuofei Biotechnology Co., Ltd. The recombinant genes were constructed into the pBR322 vector (the commercial vector was modified and a rabbit FC tag was introduced into the C-terminus), and transfected into 293T cells for expression to obtain a recombinant protein with high purity, which was used as an antigen to immunize animals. The amino acid sequence of the complete antigen is shown below:
[0070] APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCCVAKSYNRVTVMGGFKVENHTACHCSTCYYHKS GGGGSGGGGSGGGGSCELTNITIAIEKERFCISINTTWCAGYCYTRDLVYKDPARPKIQKTCTFKELVYETVRVPGCAHHADSLYTYPVATQCHCGKCDSDSTDCTVRGLGPSYCSFGEMKE (see SEQ ID NO. 11).
[0071] (1) Construction of protein expression plasmid
[0072] A plasmid containing human FSH sequence (from gene synthesis) was used as a template and PCR amplification was performed with FSH-F / R primer pair. The PCR reaction system included 1 μL template, 1 μL forward primer (10 mM), 1 μL reverse primer (10 mM), 25 μL 2× Gloria Hi-Fi PCR Master Mix with GC Buffer (from ABclonal, product number RK20717), and 22 μL pure water (N.FH 2 O), PCR amplification program: 98°C pre-denaturation for 30s, followed by 30 cycles of 98°C for 10s, 64°C for 30s, and 72°C for 30s, and finally kept at 72°C for 5min. The reaction solution was stored at 4°C. The primer pair sequences are as follows, F and R represent forward and reverse primers, respectively:
[0073] FSH-F: gttcccggtagcaccggtgctcctgatgtgcaggattgcc (see SEQ ID NO. 12);
[0074] FSH-R: tgctgatccgccacctccctccttcatctcgccaaagctg (see SEQ ID NO. 13).
[0075] After the amplified PCR product was purified, it was loaded into the eukaryotic expression vector pBR322 by homologous recombination. The plasmid was preserved after sequencing verification. The sequencing work was completed by Jinkairui Biotechnology Co., Ltd.
[0076] (2) Expression vector transfection and protein expression
[0077] Add 85 mL of HEK293T (purchased from Invitrogen) cell suspension to a 500 mL cell shake flask to make the cell density reach 2.6 × 10 6cells / mL, 100 μg of the vector was added to 5 mL of Opti-MEM (purchased from Thermo Fisher) culture medium, and the plasmid suspension was mixed after the addition; the transfection reagent was slowly added dropwise to the plasmid suspension, and the centrifuge tube was shaken while adding dropwise to make the vector and the transfection reagent evenly combined, and the above liquid was slowly added dropwise to the HEK293T cells to make the mixture fully and evenly contact the cells to obtain recombinant cells; the cells were placed in an incubator, and after culturing for 16-20 hours, the transfection enhancer was added; samples were taken and counted four days after transfection, and the cell viability dropped below 60% or the total number of cells was less than 1×10 6 cells / mL, centrifuge at 4°C and 3000 rpm / min for 15 min, collect the recombinant cell supernatant, add 0.1 mM final concentration of protease inhibitor AEBSF, cover the centrifuge tube, gently turn upside down to mix AEBSF, and store the recombinant cell supernatant at 4°C.
[0078] (3) Recombinant protein purification
[0079] ProteinAt Beads 4FF matrix (purchased from Tiandi Renhe, catalog number SA023100) was used to extract and purify recombinant FSH protein from the culture supernatant of recombinant cells by affinity chromatography. The purification method is shown in the instruction manual. The SDS-PAGE electrophoresis of the purified protein is shown in Figure 1 As shown in the figure, lane "BSA" represents bovine serum albumin standard, lane "MK" represents marker, and lane "2μg" represents 2μg of sample. After separation and purification, the purity of the recombinant FSH protein is about 90%, and the protein concentration is 1.74mg / mL measured by ultra-micro spectrophotometer (ThermoFisher, NanoDrop 2000c).
[0080] Example 2 Preparation of rabbit monoclonal antibody against human follicle stimulating hormone (FSH)
[0081] New Zealand white rabbits were immunized with recombinant human FSH protein (prepared and purified in Example 1) as an antigen, and then single antigen-specific B lymphocytes were sorted out based on the monoclonal antibody development technology of single B lymphocyte screening and culture, and the antibody encoding gene in the cell was amplified by PCR technology, and recombinant expression was performed to screen and obtain the target antibody strain. The antibody sequencing work was completed by Jinkairui Biotechnology Co., Ltd., and the amino acids (AA) of the antibodies are shown in Table 1, in which LCDR1-3 respectively represent the light chain complementary determining regions CDR1-3, and HCDR1-3 respectively represent the heavy chain complementary determining regions CDR1-3.
[0082] Table 1 Sequence information of rabbit monoclonal antibodies in this example
[0083]
[0084] (1) Antigen Immunization
[0085] Recombinant human FSH protein (prepared and purified in Example 1) was used as an immunogen to immunize three New Zealand white rabbits; 200 μg of the immunogen was added to each white rabbit for the first immunization. Before the first immunization, the immunogen was mixed with an equal amount of complete Freund's adjuvant (purchased from Sigma) to prepare an emulsifier, which was injected subcutaneously at multiple points in the rabbit's abdomen and back; after the first immunization, 100 μg of the immunogen was mixed with an equal amount of incomplete Freund's adjuvant (purchased from Sigma) to prepare an emulsifier, which was injected subcutaneously at multiple points in the rabbit's abdomen and back every 3 weeks, and boosted twice. After the three immunizations, rabbit serum samples were collected, and the serum was diluted 1:243000 and then measured for FSH titer using ELISA, and OD 450nm For rabbits with a GSH level exceeding 0.2, 200 μg of the immunogen was injected subcutaneously at multiple points for booster immunization. Three days later, the animals were sacrificed and the spleens were removed.
[0086] (2) Detection of rabbit polyclonal antibody titer against human FSH
[0087] The indirect enzyme-linked immunosorbent assay (ELISA) was used for determination. The specific operations included: 1) NeutrAvidin protein coating: NeutrAvidin protein (purchased from Thermo Fisher, catalog number 31001) was diluted with 1× PBS buffer to a final concentration of 2 μg / mL, and the diluted NeutrAvidin protein was added to a 384-well plate at 25 μL / well. After the 384-well plate was leveled, the plate was briefly centrifuged (stopped after the rpm reached 1000) and kept at 4°C overnight; 2) Biotinylated antigen: dilute recombinant human FSH protein with 1× PBS buffer to a final concentration of 1 μg / mL, add 25 μL / well to a 384-well plate, and incubate at room temperature for 1 hour; 3) Blocking: take out the plate that has been stored overnight at 4°C, add 75 μL of washing buffer (PBS containing 0.05% (v / v) Tween-20) to each well using a plate washer and wash 5 times; then add 50 μL / well of blocking buffer (PBS containing 1% BSA, 0.5% gelatin and 5% sucrose), and incubate at room temperature for 1 hour. Used to block irrelevant binding sites; 4) Detection serum gradient dilution and sample loading: Repeat 3) plate washing process to clean the well plate, and perform gradient dilution of the detection serum in a 96-well plate. Use dilution buffer (PBS containing 1% BSA) to dilute the serum starting from 1:1000 and perform three-fold dilution, a total of 8 gradients, and the dilution ratio can be adjusted according to actual conditions; 5) Secondary antibody incubation: Repeat 3) plate washing process to clean the well plate, and use dilution buffer to incubate horseradish peroxidase (HRP)-coupled goat anti-rabbit IgG (purchased from Jackson, No. 111-035-045) was diluted to a dilution ratio of 1:5000, and diluted goat anti-rabbit IgG-HRP was added to the plate at 25 μL / well to bind the target protein in the plate, and incubated at room temperature in the dark for 1 hour; 6) Stop the reaction and color development: Repeat the plate washing process in 3) to clean the plate, add TMB at 100 μL / well for color development, 37°C in the dark for 10 minutes, add 0.5M oxalic acid solution at 100 μL / well to stop the reaction, measure the absorption value at 450nm, and use the rabbit serum before immunization as the negative control. The serum titer test results are shown in Figure 2 It can be seen that the serum titer of the three rabbits N23120 was the highest, and a strong immune response was produced in the rabbit, so this rabbit number was selected for subsequent antibody preparation.
[0088] (3) Isolation of B lymphocytes from spleen and sorting of B lymphocytes
[0089] Conventional methods are used to isolate B lymphocytes from the spleen, and antigen-specific B lymphocytes are sorted. For related methods, please refer to the published patents "Method for efficiently isolating single antigen-specific B lymphocytes from spleen cells (publication number: CN110016462A, publication date: 2019-07-16)" and "A B lymphocyte in vitro culture system and application (publication number: CN111518765A, publication date: 2020-08-11)".
[0090] (4) Cloning of the gene encoding rabbit monoclonal antibody
[0091] The supernatant of cultured B cells was used to identify positive clones by antigen-coated ELISA. The cells of positive clones were collected and lysed and then analyzed by Quick-RNA TM Micro Prep Kit (purchased from ZYMO, catalog number R1051) was used to extract RNA and reverse transcribe it into cDNA. Using the aforementioned cDNA as a template, the naturally paired rabbit monoclonal antibody light chain variable region (VL) and heavy chain variable region (VH) were amplified from the cDNA of the corresponding positive clone by PCR and sequenced. The PCR reaction system included: 4 μL cDNA, 1 μL forward primer (10 mM), 1 μL reverse primer (10 mM), 12.5 μL 2× Gloria HiFi (from ABclonal, catalog number RK20717) and 6.5 μL H 2 O; PCR amplification program includes: pre-denaturation at 98°C for 30s, followed by 40 cycles of 98°C for 10s, 64°C for 30s, and 72°C for 30s, and finally kept at 72°C for 5min. The reaction solution was stored at 4°C. The primer sequences (5'-3') for amplifying VL and VH genes are shown below.
[0092] VL-F: tgaattcgagctcggtacccatggacacgagggcccccac (see SEQ ID NO. 14);
[0093] VL-R: cacacacgatggtgactgttccagttgccacctgatcag (see SEQ ID NO. 15);
[0094] VH-F: tgaattcgagctcggtacccatggagactgggctgcgctg (see SEQ ID NO. 16);
[0095] VH-R: gtagcctttgaccaggcagcccagggtcaccgtggagctg (see SEQ ID NO. 17).
[0096] (5) Expression and large-scale production of rabbit monoclonal antibodies
[0097] After the antibody VL and VH genes were purified, they were loaded onto the expression vector pBR322 carrying the light chain constant region (CL) and heavy chain constant region (CH) genes, respectively. The expression vector map is shown in Figure 3 In the figure, pBR322 origin and f1 origin are replication promoters, Ampcillin is a resistance gene, CMV promoter is a transcription promoter, SV40 PA terminator is a tailing signal, Light chain constant is the nucleic acid sequence of the light chain constant region (left figure), and Heavy chain constant is the nucleic acid sequence of the heavy chain constant region (right figure). CL and CH genes were obtained by querying the IMGT online database (www.imgt.org). The construction process of the antibody expression vector is as follows: the expression vector pBR322 carrying the CL and CH genes is linearized with XbaI and NheI restriction enzymes respectively, and the VL and VH genes containing the signal peptide amplified by the above PCR are purified and constructed into the aforementioned expression vector XbaI (955bp) and NheI (949bp) by homologous recombination to obtain an expression vector containing complete light chain and heavy chain genes, and the expression vector construction is successfully verified by sequencing.
[0098] The signal peptide of this embodiment can adopt the antibody expression signal peptide sequence commonly used in the art, such as the patent "High-affinity Human IL-5 rabbit monoclonal antibody and its application (publication number: CN115819578A, publication date: 2023-03-21)" has a signal peptide "MDTRAPTQLLGLLLLWLPGARC" upstream of the light chain variable region and a signal peptide "METGLRWLLLVAVLKGVQC" upstream of the heavy chain variable region.
[0099] The constructed light chain (FL) and heavy chain (FH) expression vectors were transfected into 293F cells together. After transfection, the cells were cultured for 72-96 hours to obtain the culture supernatant containing the recombinant rabbit monoclonal antibody that recognizes human FSH protein. Protein A affinity gel resin (purchased from Tiandi Renhe, catalog number SA023100) was used to purify the target antibody from the culture supernatant. The antibody concentration was 1 mg / mL and the purity was greater than 95% using 12% SDS-PAGE gel electrophoresis.
[0100] Example 3 Reaction Specificity and Application Analysis of Rabbit Monoclonal Antibodies Against Human FSH
[0101] (1) Immunohistochemistry analysis (IHC) using rabbit monoclonal antibodies
[0102] Human FSH protein is mainly highly expressed in human anterior pituitary basophils, and subcellular localization is in the cytoplasm. The tissue section samples used in this embodiment include: human pituitary tissue section samples (positive control), human liver tissue section samples and mouse pituitary tissue section samples. The tissue sample chips were purchased from Bioss, and the IHC staining and analysis operations were performed according to the instructions, including dewaxing and hydration-antigen repair-inactivation of endogenous peroxidase and biotin-serum blocking-incubation of primary antibody-incubation of secondary antibody-DAB color development-hematoxylin counterstaining-dehydration-sealing-microscope examination.
[0103] The specific operation of IHC is as follows: 1) Sample preparation and baking: Place the paraffin sections on the slice rack in the same direction and bake them in a 56°C thermostat for 30 minutes; at the same time, place the dewaxing solution 1 cylinder in a 56°C thermostat; place the paraffin sections together with the slice rack in the dewaxing solution 1 cylinder, then take them out of the thermostat and place them at room temperature. After 5 minutes, take out the sections and immerse them in the room temperature dewaxing solution 2 cylinder, and place the paraffin sections in the cylinders in the order of dewaxing solution 2, dewaxing solution 3, anhydrous ethanol 1, anhydrous ethanol 2, and anhydrous ethanol 3. When placed in the dewaxing solution reagent cylinder, each cylinder is placed for 5 minutes, and when placed in the anhydrous ethanol reagent cylinder, each cylinder is placed for 3 minutes; wash the sections with running water for 3 minutes; dewaxing solutions 1-3 were purchased from Wuxi Jiangyuan Industrial Technology Trade Co., Ltd.; 2) Antigen repair: 0.01M Tris-EDTA repair solution (pH 9.0) High-pressure heat repair; 3) Inactivation of endogenous peroxidase: Wash with PBS buffer 3 times, 1 min each time, remove the buffer on the slice; immerse the slice completely in 3% hydrogen peroxide solution and incubate at room temperature for 10 min; 4) Blocking: Wash with PBS buffer 3 times, 3 min each time, remove the buffer on the slice; circle the tissue area to be tested on the slide with an immunohistochemical pen, and add PBS blocking solution to the circled area; place the slice horizontally in an incubation humidified box with water at the bottom, incubate at room temperature for 30 min, and start timing from the addition of the blocking solution. ; 5) Primary antibody incubation: remove the blocking solution, add anti-FSH protein rabbit monoclonal antibody (antibody working concentration 6μg / mL) diluted 1:900 with antibody diluent-PBS working solution on the tissue section, place it horizontally in the incubation wet box, and incubate it at room temperature for 60 minutes; remove the antibody working solution, rinse quickly once with PBS buffer, and soak and wash 3 times with PBS buffer, each time for 3 minutes; during the soaking and washing period, it is necessary to repeatedly pull up and down several times; 6) Secondary antibody incubation: add ready-to-use secondary antibody working solution (purchased from Dako, item number K5007) on the tissue section Then place it horizontally in an incubation humidified box and incubate it at room temperature for 25 minutes; remove the secondary antibody working solution on the slice, quickly rinse it with PBS buffer once, and soak and wash it with PBS buffer three times, each time for 3 minutes; during the soaking and washing period, it is necessary to repeatedly pull it up and down several times; 7) Color development: add DAB color development solution to the slice, observe the color change closely under a microscope, and after obtaining the appropriate staining intensity, immerse the slice in a large amount of distilled water to stop the color development, and then wash it in running water for 10 minutes; 8) Counterstaining: immerse the slightly drained tissue slice in Mayer's hematoxylin counterstaining for 1 minute. min, then wash with running water for 3min; 9) Blueing: Immerse the slightly drained slices in a saturated aqueous solution of lithium carbonate for 3s, and wash with running water for 3min; 10) Dehydration: Soak the washed slices in anhydrous ethanol once, lift them up and down several times during the soaking period, and take them out after 10s; place them in a constant temperature blast drying oven at high temperature (54-58℃) to completely dry; 11) Sealing: Add an appropriate amount of neutral gum to the center of the slice, and cover it with a cover glass. The amount of glue added should be appropriate. After sealing the cover glass, the tissue should be completely covered, and no glue should overflow; 12) Slice scanning. .
[0104] Immunohistochemical staining results are divided into: positive and negative, where the positive signal requires brown staining at the antigen site of specific tissues and cells and a low background color at the site that theoretically should not be stained. Figure 4The IHC staining results of human pituitary tissue slice sample, human liver tissue slice sample and mouse pituitary tissue slice sample are respectively shown from left to right. It can be seen that the positive signal of antibody immune response in pituitary tissue is distributed in the cytoplasm of anterior lobe basophils, accurately positioned, clearly stained and without nonspecific staining, without specific staining in liver tissue, presenting negative signal, and being judged as negative sample. It is confirmed that the specificity of the anti-human FSH rabbit monoclonal antibody of the invention is high, and the anti-cell component interference ability is strong, which is conducive to improving the accuracy and reliability of detection, and effectively reduces the absence of false positive and false negative results. And the antibody of the present invention is widely applicable, and positive signals are presented in the pituitary tissue of humans and mice, and is suitable for the immunohistochemical analysis of human and mouse tissue samples.
[0105] (2) Immunofluorescence analysis (IF) using rabbit monoclonal antibodies
[0106] The dewaxing and hydration of tissue samples - antigen repair - serum blocking operations refer to the IHC analysis process in 3.1, and then 3) primary antibody incubation: remove the blocking solution, add the anti-FSH protein rabbit monoclonal antibody working solution prepared in PBS buffer to the circled area (primary antibody dilution ratio 1:200, primary antibody working concentration is 0.5μg / mL), place it horizontally in the incubation wet box, and incubate it at 4℃ overnight; then take out the incubation wet box and warm it up at room temperature for 15 minutes, remove the antibody working solution on the slice, and rinse and wash it in PBST buffer for 3 times, each time for 3-5 minutes; during the immersion and washing period, it is necessary to repeatedly pull up and down several times; 4) secondary antibody incubation: add goat anti-rabbit secondary antibody working solution (Cy3 Goat Anti-Rabbit IgG (H+L), purchased from Jackson, catalog number 111-165-144, secondary antibody dilution ratio 1:200) to the sample, the sample must be completely covered, protected from light, and incubated at room temperature for 1 hour; 5) Confocal observes fluorescence and collects images.
[0107] Results Figure 5 , where the left picture shows the confocal imaging of human pituitary tissue using FSH rabbit monoclonal antibody (red), and the right picture shows the localization information of FSH protein using DAPI nuclear staining (blue) of human pituitary tissue and merging red and blue. It can be seen that the antibody of the present invention can specifically bind to FSH in human pituitary tissue, which is consistent with its theoretical localization, further proving that the antibody has good recognition specificity and excellent anti-interference ability for human FSH.
[0108] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.
Claims
1. A rabbit monoclonal antibody against human follicle stimulating hormone, characterized in that: It comprises a light chain variable region and a heavy chain variable region, wherein the amino acid sequences of the complementary determining regions CDR1, CDR2 and CDR3 on the light chain variable region are shown as SEQ ID NO.3, SEQ ID NO.4 and SEQ ID NO.5, respectively; the amino acid sequences of the complementary determining regions CDR1, CDR2 and CDR3 on the heavy chain variable region are shown as SEQ ID NO.8, SEQ ID NO.9 and SEQ ID NO.10, respectively.
2. The rabbit monoclonal antibody against human follicle stimulating hormone according to claim 1, characterized in that: The amino acid sequence of the light chain variable region is shown in SEQ ID NO.2, and the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO.
7.
3. The rabbit monoclonal antibody against human follicle stimulating hormone according to claim 2, characterized in that: The rabbit monoclonal antibody further comprises a light chain constant region and a heavy chain constant region, wherein the light chain constant region and the light chain variable region constitute a light chain, and the heavy chain constant region and the heavy chain variable region constitute a heavy chain, wherein the light chain constant region is a κ chain, and the heavy chain is of IgG type.
4. The rabbit monoclonal antibody against human follicle stimulating hormone according to claim 3, characterized in that: The amino acid sequence of the light chain is shown in SEQ ID NO.1, and the amino acid sequence of the heavy chain is shown in SEQ ID NO.
6.
5. The rabbit monoclonal antibody against human follicle stimulating hormone according to claim 1, characterized in that: The rabbit monoclonal antibody is a full-length antibody or an antigen-binding region thereof; the antigen-binding region is selected from at least one of a Fab fragment, a F(ab)2 fragment, a Fv fragment, a (Fv)2 fragment, a scFv fragment and a sc(Fv)2 fragment.
6. A nucleic acid molecule, a recombinant vector comprising the nucleic acid molecule or a host cell comprising the nucleic acid molecule, characterized in that: The nucleic acid molecule encodes the rabbit monoclonal antibody against human follicle stimulating hormone as described in any one of claims 1-5.
7. The nucleic acid molecule, the recombinant vector comprising the nucleic acid molecule or the host cell comprising the nucleic acid molecule according to claim 6, characterized in that: The recombinant vector is an expression vector pBR322, and the host cell is a human kidney epithelial cell.
8. Use of the rabbit monoclonal antibody against human follicle stimulating hormone according to any one of claims 1 to 5 in the preparation of a reagent and / or a kit for immunoassay of human follicle stimulating hormone.
9. A human follicle stimulating hormone immunoassay kit, characterized in that: The invention comprises the rabbit monoclonal antibody against human follicle stimulating hormone or its antibody conjugate according to any one of claims 1 to 4, wherein the antibody conjugate is formed by connecting the rabbit monoclonal antibody to a detection label.
10. The human follicle stimulating hormone immunoassay kit according to claim 9, characterized in that: The kit is an immunohistochemistry kit or an immunofluorescence kit.
Citation Information
Patent Citations
Process for preparing human follicle-stimualting hormone beta subunit monoclonal antibody
CN1418965A
Monoclonal antibodies against a follicle-stimulating hormone
EP0328248A2
Antibodies against the human FSHR extracellular domain
US20200010556A1
Preparation and use of Anti-FSHR antibody and antibody-drug conjugate thereof
US20240043548A1
AU2843989A
